Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma.
Rushton, Sarah Burghel, G Wallace, A
Rushton, Sarah
Burghel, G
Wallace, A
Citations
Altmetric:
Abstract
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive adult solid cancers. Due to its rarity, there are only a handful of molecular genetics studies on ATCs (1-3) . BRAF V600E mutation is one of the commonly reported genetic alterations, reported in10-68% of ATCs(1-4) . Currently there is no effective treatment for ATC.,Therapy targeting BRAF may provide a potential therapeutic option as a dramatic response to BRAF inhibitor (vemurafenib) has been reported in a case of BRAF-mutated ATC (5) . A number of studies have shown that BRAF V600E mutant-specific antibody VE1 can identify BRAF V600E mutation in a spectrum of cancers, including thyroid cancers (6) . We investigated the utility of this antibody for BRAF V600E screening in ATCs. This article is protected by copyright. All rights reserved.
Description
Date
2016-03-14
Publisher
Collections
Keywords
Type
Article
Citation
Immunohistochemical Detection of BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma. 2016: Histopathology